Weed (BUDZ) Return on Capital Employed (2011 - 2026)
Weed's (BUDZ) quarterly Return on Capital Employed came in at 128.98% in Q1 2026, down 17327.0% year-on-year from N/an in Q1 2025, and down 31.52% quarter-over-quarter from 188.35% in Q4 2025.
Weed (BUDZ) Return on Capital Employed (2011 - 2026) Analysis & Trends
Weed's Return on Capital Employed history runs 11 years deep, the most recent figure standing at 128.98% for Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 17327.0% year-over-year to 128.98% in Q1 2026; TTM through Mar 2026 was 128.98%, a 17327.0% decrease from a year earlier, with the FY2025 full-year figure at 221.6%, down 16201.0% from the prior year.
- Return on Capital Employed slipped to 128.98% in Q1 2026 per BUDZ's latest filing, from 188.35% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 980.82% in Q2 2023 and bottomed at 1010.89% in Q2 2024.
- The 5-year median for Return on Capital Employed is 136.02% (2023), against an average of 66.84%.
- Across the five-year window, Return on Capital Employed plunged 199171 bps in 2024 and jumped 118312 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 262.12% in 2022, then jumped by 47 bps to 138.63% in 2023, then jumped by 232 bps to 182.52% in 2024, then grew by 3 bps to 188.35% in 2025, then sank by 32 bps to 128.98% in 2026.
- Per Business Quant, the three latest BUDZ Return on Capital Employed figures stand at 128.98% (Q1 2026), 188.35% (Q4 2025), and 141.58% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Weed | 3.72 Mn | 3.72 Mn | - | 128.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 128.98% |
| Dec 31, 2025 | 188.35% |
| Sep 30, 2025 | 141.58% |
| Jun 30, 2025 | 172.23% |
| Mar 31, 2025 | 302.25% |
| Dec 31, 2024 | 182.52% |
| Sep 30, 2024 | 515.18% |
| Jun 30, 2024 | -1,010.89% |
| Mar 31, 2024 | -286.71% |
| Dec 31, 2023 | -138.63% |
| Sep 30, 2023 | -136.02% |
| Jun 30, 2023 | 980.82% |
| Mar 31, 2023 | -967.60% |
| Dec 31, 2022 | -262.12% |
| Sep 30, 2022 | -144.42% |
| Jun 30, 2022 | -196.05% |
| Mar 31, 2022 | -605.82% |
| Dec 31, 2021 | -514.20% |
| Sep 30, 2021 | -311.30% |
| Jun 30, 2021 | -292.12% |